The American Journal of Medicine
Volume 122, Issue 5, Supplement , Pages S23-S25 , May 2009

The Potential Role of Nitric Oxide in Cardiovascular Safety When Treating Patients with Osteoarthritis and Hypertension: A Moderated Panel Discussion

  • William B. White, MD

      Affiliations

    • Division of Hypertension and Clinical Pharmacology, Pat and Jim Calhoun Cardiology Center, University of Connecticut School of Medicine, Farmington, Connecticut, USA
    • Corresponding Author InformationRequests for reprints should be addressed to William B. White, MD, Division of Hypertension and Clinical Pharmacology, Pat and Jim Calhoun Cardiology Center, University of Connecticut School of Medicine, 263 Farmington Avenue, Farmington, Connecticut 06030-3940
    • ,
  • Carl J. Pepine, MD

      Affiliations

    • Division of Cardiovascular Medicine, University of Florida College of Medicine, Gainesville, Florida, USA
    • ,
  • Michael A. Weber, MD

      Affiliations

    • Downstate College of Medicine, State University of New York, Brooklyn, New York, USA

References 

  1. Chan AT, Manson JE, Albert CM, et al. Nonsteroidal antiinflammatory drugs, acetaminophen, and the risk of cardiovascular events. Circulation. 2006;113:1578–1587
  2. Solomon SD, Wittes J, Finn PV, et al. Cross Trial Safety Assessment Group Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis. Circulation. 2008;117:2104–2113
  3. White WB. Cardiovascular effects of the cyclooxygenase inhibitors. Hypertension. 2007;49:408–418
  4. Curhan GC, Knight EL, Rosner B, et al. Lifetime nonnarcotic analgesic use and decline in renal function in women. Arch Intern Med. 2004;164:1519–1524
  5. Antman E, Bennett JS, Daugherty A, Furberg C, Roberts H, Taubert KA American Heart Association. Use of nonsteroidal antiinflammatory drugs: an update for clinicians (A scientific statement from the American Heart Association). Circulation. 2007;15:1634–1642
  6. Muscara MN, McKnight W, Sel Soldato P, Wallace JL. Effect of a nitric oxide-releasing naproxen derivative on hypertension and gastric damage induced by chronic nitric oxide inhibition in the rat. Life Sci. 1998;62:PL235–PL240
  7. Muscara MN, McKnight W, Lovren F, Triggle CR, Cirino G, Wallace JL. Antihypertensive properties of a nitric oxide-releasing naproxen derivative in two-kidney, one-clip rats. Am J Physiol Heart Circ Physiol. 2000;279:H528–H535
  8. Presotto C, Bolla MI, Oliveri R, et al. HCT 3012 reduces blood pressure in the spontaneously hypertensive rat model. Arthritis Rheum. 2006;54(suppl 9):S147;Presentation 231.
  9. Davies NM, Roseth AG, Appleyard , et al. NO-naproxen vs. naproxen: ulcerogenic, analgesic and anti-inflammatory effects. Aliment Pharmacol Ther. 1997;11:69–79
  10. Fiorucci S, Di Lorenzo A, Ranga B, et al. Nitric oxide (NO)-releasing naproxen (HCT-3012 [(S)-6-methoxy-α-methyl-2-naphthaleneacetic Acid 4-(nitrooxy)butyl ester]) interactions with aspirin in gastric mucosa of arthritic rats reveal a role for aspirin-triggered lipoxin, prostaglandins, and NO in gastric protection. J Pharmacol Exp Ther. 2004;311:1264–1271
  11. Schnitzer TJ, Kivitz AJ, Lipetz RS, Sanders N, Hee A. Comparison of the COX-inhibiting nitric oxide donator AZD3582 and rofecoxib in treating the signs and symptoms of osteoarthritis of the knee. Arthritis Rheum. 2005;15:53:827–837.
  12. Lohmander LS, McKeith D, Svensson O, et al. STAR Multinational Study Group A randomised, placebo controlled, comparative trial of the gastrointestinal safety and efficacy of AZD3582 versus naproxen in osteoarthritis. Ann Rheum Dis. 2005;64(3):449–456

 As of time of publication, rofecoxib has been removed from the market by the manufacturer.

 Statement of author disclosure: Please see the Author Disclosures section at the end of this article.

PII: S0002-9343(09)00209-5

doi: 10.1016/j.amjmed.2009.03.005

The American Journal of Medicine
Volume 122, Issue 5, Supplement , Pages S23-S25 , May 2009

Article Tools